



Tell Congress to Pass the MVP Act of 2023

The Medicaid VBPs for Patients (MVP) Act of 2023 ([H.R. 2666](#)) is a bipartisan bill that will enhance Medicaid patients' access to expensive yet necessary therapies by modernizing the Medicaid program's existing value-based purchasing (VBP) arrangement framework. Specifically, the legislation would codify the current "multiple best price" rule which grants manufacturers the freedom to report the lowest drug price paid by a payer for drugs subject to VBP arrangements when other criteria are met. The MVP Act also clarifies that the best price is the maximum possible price paid, and it would update requirements for manufacturers to report information relayed to pricing structures for VBPs to CMS. AMCP applauded the MVP Act's introduction by US Representatives Brett Guthrie (R-KY), Anna Eshoo (D-CA), John Joyce (R-PA), Jake Auchincloss (D-MA), and Mariannette Miller-Meeks (R-IA) in April with [a press release](#), and is now calling on members to urge their legislators in Congress to pass the bill. Visit AMCP's Take Action page and use the form provided to email or Tweet your Members of Congress with a request for their support of this legislation.

[Take action now.](#)

APPROVED

**For Non-Muscle Invasive
Bladder Cancer (NMIBC)**

Learn More

Ferring and the Ferring Pharmaceuticals logo are registered trademarks of Ferring B.V.
© 2023 Ferring B.V. All rights reserved. US-ADST-2300030 05/23

FERRING
PHARMACEUTICALS

AMCP Gathers PDT Manufacturers for Product Demonstrations on Capitol Hill

On June 22, AMCP hosted a Prescription Digital Therapeutics Demo Day on Capitol Hill with support from the Digital Therapeutics Alliance and congressional sponsorship from Representative Kevin Hern (R-OK), the lead sponsor in the House of the Access to PDTs Act of 2023 ([S.723/H.R.1458](#)). Ten PDT manufacturers participated, including seven with cleared products and three with investigational products. Approximately 175-200 people visited throughout the 5-hour event and expressed enthusiasm at the opportunity for hands-on experience with and education about PDTs. Overall, the event helped demonstrate PDTs' ability to identify, treat, and manage chronic diseases such as substance use disorders, attention-deficit hyperactivity disorder (ADHD), diabetes, and more. Following the event, AMCP continues to urge Members of Congress to cosponsor the Access to PDTs Act of 2023.

[Learn more about PDTs.](#)

AMCP's Adam Colborn Discusses Biosimilar Interchangeability with AJMC

Interchangeable biologics are biosimilar products that may be substituted at the pharmacy for the reference product without physician approval. While this designation helps lower costs and increase access for patients, AMCP's Adam Colborn explains in an interview with the *American Journal of Managed Care* how the strict regulatory requirements for a biosimilar product to reach interchangeable status can impede patients from receiving many FDA-approved biosimilars. "The absence of interchangeability in the biosimilar market really is a pretty big obstacle for patients and

APPROVED



**For
Non-Muscle
Invasive
Bladder
Cancer
(NMIBC)**

[Learn More](#)

Ferring and the Ferring Pharmaceuticals logo are registered trademarks of Ferring B.V.
© 2023 Ferring B.V.
All rights reserved.
US-ADST-230030 05/23

FERRING
PHARMACEUTICALS

pharmacists who are trying to dispense them. There's a much higher regulatory benchmark for a biosimilar to receive an interchangeable designation than a small molecule drug," Colborn states in the interview, published on July 3. "Until we get that interchangeable designation, we won't see pharmacists who are able to substitute biosimilars at the pharmacy counter for brand name prescriptions for the originator product," he explained, adding that this trend could result in patients paying higher costs than they would if they received the biosimilar. Colborn also spoke to the need for a uniform national approach to biosimilars and interchangeability rather than the current patchwork of state regulations.

[Watch the full interview.](#)

Register for the Inflation Reduction Act Pre-Conference Program at AMCP Nexus 2023

The Inflation Reduction Act (IRA) stands as one of the most consequential pieces of health care legislation passed in recent history. To better understand the fundamentals of IRA and its impact, join peers and colleagues at AMCP Nexus 2023 for a pre-conference program geared towards identifying the law's implications for pharma, payers, providers, and patients through the lens of payers. The pre-conference program is held on Monday, October 16 from 1pm – 5:30pm ET, and features multi-stakeholder panels along with IRA-specific provision payer surveys for more insight into the payer impact. Registration cost is \$399 for AMCP members and \$499 for non-members. Additionally, registration for this pre-conference program is separate from the AMCP Nexus 2023 registration fee.

[Register today.](#)

Catch Up on the Latest Regulatory NewsBREAKs

With IRA implementation under full swing this summer, CMS is working tirelessly to update and release guidance on provisions related to the law's drug price negotiation and cost-sharing provisions. To stay up to date on the most pressing notices from CMS as they appear, view AMCP's latest Regulatory NewsBREAKs. Regulatory NewsBREAKs are also delivered immediately to member inboxes when published. The latest NewsBREAKs from June 30 and July 5 cover revised Medicare drug price negotiation guidance and a new price negotiation program agreement, while the July 14 NewsBREAK offers information on changes to Medicare Part B cost-sharing provisions as required by IRA.

[Read AMCP's Regulatory NewsBREAKs.](#)